After RBC Capital and Robert W. Baird gave Sarepta Therapeutics (NASDAQ: SRPT) a Buy rating last month, the company received another Buy, this time from Needham. Analyst Gil Blum maintained a Buy rating on Sarepta Therapeutics today and set a price target of $150.00. The company's shares closed last Wednesday at $75.97. According to TipRanks.com, Blum has 0 stars on 0-5 stars ranking scale with an average return of -19.9% and a 31.5% success rate. Blum covers the Healthcare sector, focusing on stocks such as Mereo Biopharma Group Plc, Rocket Pharmaceuticals, and Aeglea Biotherapeutics.
https://www.tipranks.com/news/blurbs/sarepta-therapeutics-srpt-received-its-third-buy-in-a-row-6?utm_source=advfn.com&utm_medium=referral
Sarepta Therapeutics (NASDAQ:SRPT)
Historical Stock Chart
From Aug 2022 to Sep 2022 Click Here for more Sarepta Therapeutics Charts.
Sarepta Therapeutics (NASDAQ:SRPT)
Historical Stock Chart
From Sep 2021 to Sep 2022 Click Here for more Sarepta Therapeutics Charts.